McGill IBD logo
Donate

Abbvie | Protocol M26-266 (upcoming)

Molecule: Risankizumab, Trosunilimab, ABBV-701


Study Title:

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Eli Lilly | Protocol I6T-MC-AMCD (COMMIT-UC)

Molecule: Mirikizumab and Tirzepatide


Study Title:

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)

 

Genentech | Protocol GA45977 (SUNCREST)

Mulecule: RO7837195


Study Title:

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Janssen | Protocol Duet Encore - UC

Molecule: JNJ-78934804 and Guselkumab


Study Title:

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis (DUET ENCORE-UC)

Merck | Protocol MK-7240-001

Molecule : Tulisokibart for moderately to severely active ulcerative colitis


Study Title:

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Sanofi | Protocol ACT17746 (LIBERTY-UC SUCCEED)

Molecule : Dupilumab (Anti-Il4&13)


Study Title:

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Spyre Therapeutics | Protocol PY123-201 (The SKYLINE-UC Study) - Pending Approbation

Molecule: Add on humanized antibodies


Study Title:

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Takeda | Protocol TAK-279-UC-2001

Molecule : TAK-279 oral for moderately to severely active ulcerative colitis


Study Title:

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Takeda | Protocol Vedolizumab-4054 (ExiGem) - Currently Recruiting

Molecule: Vedolizumab and Tofacitinib


Study Title:

An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy with Tofacitinib in Adult Patients with Moderately to Severely Active Ulcerative Colitis

Xencor | Protocol XmAb942-01 (Xenith)

Molecule: XmAb942 antibody


Study Title:

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate